VJHemOnc is committed to improving our service to you

EHA 2020 | CPX-351 in poor risk AML patients

VJHemOnc is committed to improving our service to you

Fabio Guolo

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses the use of CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, in poor-risk acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter